NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

Koman

Quote from your post:-

"The confusion seems to be yours and not due to AVII's explanation. In your example, if the efficacy shown by looking at the OS endpoint doubles that of the expectation, then my question would be: Why would the company seek AA when they can get a halt for efficacy for REGULAR APPROVAL. You don't seem to understand that a regular approval is BETTER than AA. Also, you don't seem to understand why AA was designed in the first place- mainly to get a very promising therapy to the patients faster than the regular pathway- something that NWBO failed to do so far by continuing to delay their own AA pathway thru continued enhancements to their initial p2 AA trial. Now why would the company delay their own trial from finishing? No need to answer this rhetorical question."

Could it be that they are aiming for Regular Approval, which you describe as 'better'and they are not aiming for AA...